C104655
环己胺
ReagentPlus®, 99%
别名:
氨基环己烷
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
线性分子式:
C6H11NH2
化学文摘社编号:
分子量:
99.17
EC Number:
203-629-0
UNSPSC Code:
12352100
PubChem Substance ID:
Beilstein/REAXYS Number:
471175
MDL number:
Assay:
99%
Form:
liquid
vapor density
3.42 (vs air)
vapor pressure
10 mmHg ( 22 °C), 23 mmHg ( 37.7 °C)
product line
ReagentPlus®
assay
99%
form
liquid
autoignition temp.
559 °F
refractive index
n20/D 1.459 (lit.)
bp
134 °C (lit.)
mp
−17 °C (lit.)
density
0.867 g/mL at 25 °C (lit.)
SMILES string
NC1CCCCC1
InChI
1S/C6H13N/c7-6-4-2-1-3-5-6/h6H,1-5,7H2
InChI key
PAFZNILMFXTMIY-UHFFFAOYSA-N
Legal Information
ReagentPlus is a registered trademark of Merck KGaA, Darmstadt, Germany
Still not finding the right product?
Explore all of our products under 环己胺
signalword
Danger
Hazard Classifications
Acute Tox. 3 Dermal - Acute Tox. 3 Oral - Eye Dam. 1 - Flam. Liq. 3 - Repr. 2 - Skin Corr. 1B
存储类别
3 - Flammable liquids
wgk
WGK 1
flash_point_f
80.6 °F - closed cup
flash_point_c
27 °C - closed cup
ppe
Faceshields, Gloves, Goggles, type ABEK (EN14387) respirator filter
法规信息
新产品
此项目有
Jang Sen Chang et al.
Environmental pollution (Barking, Essex : 1987), 259, 113867-113867 (2020-01-04)
This study aimed to evaluate the impacts of morphological-controlled ZnO nanoarchitectures on aerobic microbial communities during real wastewater treatment in an aerobic-photocatalytic system. Results showed that the antibacterial properties of ZnO nanoarchitectures were significantly more overwhelming than their photocatalytic properties.
Ala'a F Eftaiha et al.
Physical chemistry chemical physics : PCCP, 22(3), 1306-1312 (2019-12-19)
A comparative model for the chemisorption of CO2 was explored via three representative reaction pathways: carboxylation of cyclohexanone, carbonation of cyclohexanol, and carbamation of cyclohexylamine. The model substrates were activated using 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU, an amidine superbase). For each of these
Fengyuan Tang et al.
Cancer research, 74(14), 3779-3789 (2014-05-30)
New therapeutic targets are needed that circumvent inherent therapeutic resistance of glioblastoma multiforme (GBM). Here, we report such a candidate target in the uncharacterized adaptor protein hMOB3, which we show is upregulated in GBM. In a search for its biochemical